Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
Jingjun Huang,1,* Wensou Huang,1,* Meixiao Zhan,2,* Yongjian Guo,1 Licong Liang,1 Mingyue Cai,1 Liteng Lin,1 Mingji He,3 Hui Lian,3 Ligong Lu,2 Kangshun Zhu1 1Department of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Ho...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6c3a62e5d9684dd79a945eee49ffe42b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6c3a62e5d9684dd79a945eee49ffe42b |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
liver cancer high tumor burden chemoembolization drug-eluting beads hepatic arterial infusion chemotherapy survival analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
liver cancer high tumor burden chemoembolization drug-eluting beads hepatic arterial infusion chemotherapy survival analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Huang J Huang W Zhan M Guo Y Liang L Cai M Lin L He M Lian H Lu L Zhu K Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| description |
Jingjun Huang,1,* Wensou Huang,1,* Meixiao Zhan,2,* Yongjian Guo,1 Licong Liang,1 Mingyue Cai,1 Liteng Lin,1 Mingji He,3 Hui Lian,3 Ligong Lu,2 Kangshun Zhu1 1Department of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People’s Republic of China; 2Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai City, Guangdong Province, People’s Republic of China; 3Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kangshun ZhuDepartment of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Road, Guangzhou City, Guangdong, 510260, People’s Republic of ChinaTel +86-20-34156205Fax +86-20-34153709Email zhksh010@163.comLigong LuZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, 79 Kangning Road, Zhuhai City, Guangdong Province, 519000, People’s Republic of ChinaTel +86 7-56-2222569Fax +86 7-56-2162086Email lu_ligong@163.comPurpose: To evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with oxaliplatin plus fluorouracil and leucovorin (FOLFOX)-based hepatic arterial infusion chemotherapy (D-TACE-HAIC) for unresectable large (5.1– 10 cm) or huge (> 10 cm) hepatocellular carcinoma (HCC).Methods: This retrospective study evaluated consecutive patients with unresectable large or huge HCC who underwent D-TACE-HAIC (D-TACE-HAIC group) or DEB-TACE (DEB-TACE group) from January 2017 to December 2020. At imaging, tumor infiltrating appearance was classified into smooth tumor margin, non-smooth tumor margin, and macrovascular invasion. Adverse events, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups.Results: A total of 133 patients (mean age, 53 years ± 12; 117 men) were included: 69 underwent D-TACE-HAIC and 64 underwent DEB-TACE. The patients who underwent D-TACE-HAIC had higher ORR (71.0% vs 53.1%; P = 0.033), longer PFS (median, 9.3 vs 6.3 months; P = 0.005), and better OS (median, 19.0 vs 14.0 months; P = 0.008) than those who underwent DEB-TACE. In subgroup analysis, patients with non-smooth tumor margin (median, 20.8 vs 13.0 months; P = 0.031) or macrovascular invasion (median, 15.0 vs 11.0 months; P = 0.015) had significantly longer OS in D-TACE-HAIC group than in DEB-TACE group; but in patients with smooth tumor margin, OS between the two groups was similar (median, 37.0 vs 35.0 months; P = 0.458). DEB-TACE, non-smooth tumor margin, and macrovascular invasion were independent prognostic factors for poor OS in uni- and multivariable analyses. The incidence of grade 3/4 adverse events was not statistically different between the two groups (37.7% vs 28.1%; P = 0.242).Conclusion: D-TACE-HAIC was tolerable and led to better OS than DEB-TACE in patients with large or huge HCC, especially in those with non-smooth tumor margin or macrovascular invasion.Keywords: liver cancer, high tumor burden, chemoembolization, drug-eluting beads, hepatic arterial infusion chemotherapy, survival analysis |
| format |
article |
| author |
Huang J Huang W Zhan M Guo Y Liang L Cai M Lin L He M Lian H Lu L Zhu K |
| author_facet |
Huang J Huang W Zhan M Guo Y Liang L Cai M Lin L He M Lian H Lu L Zhu K |
| author_sort |
Huang J |
| title |
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| title_short |
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| title_full |
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| title_fullStr |
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| title_full_unstemmed |
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma |
| title_sort |
drug-eluting bead transarterial chemoembolization combined with folfox-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/6c3a62e5d9684dd79a945eee49ffe42b |
| work_keys_str_mv |
AT huangj drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT huangw drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT zhanm drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT guoy drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT liangl drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT caim drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT linl drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT hem drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT lianh drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT lul drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma AT zhuk drugelutingbeadtransarterialchemoembolizationcombinedwithfolfoxbasedhepaticarterialinfusionchemotherapyforlargeorhugehepatocellularcarcinoma |
| _version_ |
1718410529219805184 |
| spelling |
oai:doaj.org-article:6c3a62e5d9684dd79a945eee49ffe42b2021-11-25T18:55:29ZDrug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma2253-5969https://doaj.org/article/6c3a62e5d9684dd79a945eee49ffe42b2021-11-01T00:00:00Zhttps://www.dovepress.com/drug-eluting-bead-transarterial-chemoembolization-combined-with-folfox-peer-reviewed-fulltext-article-JHChttps://doaj.org/toc/2253-5969Jingjun Huang,1,* Wensou Huang,1,* Meixiao Zhan,2,* Yongjian Guo,1 Licong Liang,1 Mingyue Cai,1 Liteng Lin,1 Mingji He,3 Hui Lian,3 Ligong Lu,2 Kangshun Zhu1 1Department of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People’s Republic of China; 2Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai City, Guangdong Province, People’s Republic of China; 3Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kangshun ZhuDepartment of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Road, Guangzhou City, Guangdong, 510260, People’s Republic of ChinaTel +86-20-34156205Fax +86-20-34153709Email zhksh010@163.comLigong LuZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, 79 Kangning Road, Zhuhai City, Guangdong Province, 519000, People’s Republic of ChinaTel +86 7-56-2222569Fax +86 7-56-2162086Email lu_ligong@163.comPurpose: To evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with oxaliplatin plus fluorouracil and leucovorin (FOLFOX)-based hepatic arterial infusion chemotherapy (D-TACE-HAIC) for unresectable large (5.1– 10 cm) or huge (> 10 cm) hepatocellular carcinoma (HCC).Methods: This retrospective study evaluated consecutive patients with unresectable large or huge HCC who underwent D-TACE-HAIC (D-TACE-HAIC group) or DEB-TACE (DEB-TACE group) from January 2017 to December 2020. At imaging, tumor infiltrating appearance was classified into smooth tumor margin, non-smooth tumor margin, and macrovascular invasion. Adverse events, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups.Results: A total of 133 patients (mean age, 53 years ± 12; 117 men) were included: 69 underwent D-TACE-HAIC and 64 underwent DEB-TACE. The patients who underwent D-TACE-HAIC had higher ORR (71.0% vs 53.1%; P = 0.033), longer PFS (median, 9.3 vs 6.3 months; P = 0.005), and better OS (median, 19.0 vs 14.0 months; P = 0.008) than those who underwent DEB-TACE. In subgroup analysis, patients with non-smooth tumor margin (median, 20.8 vs 13.0 months; P = 0.031) or macrovascular invasion (median, 15.0 vs 11.0 months; P = 0.015) had significantly longer OS in D-TACE-HAIC group than in DEB-TACE group; but in patients with smooth tumor margin, OS between the two groups was similar (median, 37.0 vs 35.0 months; P = 0.458). DEB-TACE, non-smooth tumor margin, and macrovascular invasion were independent prognostic factors for poor OS in uni- and multivariable analyses. The incidence of grade 3/4 adverse events was not statistically different between the two groups (37.7% vs 28.1%; P = 0.242).Conclusion: D-TACE-HAIC was tolerable and led to better OS than DEB-TACE in patients with large or huge HCC, especially in those with non-smooth tumor margin or macrovascular invasion.Keywords: liver cancer, high tumor burden, chemoembolization, drug-eluting beads, hepatic arterial infusion chemotherapy, survival analysisHuang JHuang WZhan MGuo YLiang LCai MLin LHe MLian HLu LZhu KDove Medical Pressarticleliver cancerhigh tumor burdenchemoembolizationdrug-eluting beadshepatic arterial infusion chemotherapysurvival analysisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Hepatocellular Carcinoma, Vol Volume 8, Pp 1445-1458 (2021) |